Relapsed Non-Hodgkin Lymphoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
BGB-21447Phase 11 trial
Active Trials
NCT05828589Active Not Recruiting112Est. May 2026
Precision BioSciences
1 program
1
CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT05420493Unknown54Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BeOne MedicinesBGB-21447
Precision BioSciencesCAR-T cells

Clinical Trials (2)

Total enrollment: 166 patients across 2 trials

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Start: Jun 2023Est. completion: May 2026112 patients
Phase 1Active Not Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Start: Sep 2021Est. completion: Sep 202554 patients
Phase 1Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space